143 related articles for article (PubMed ID: 21660132)
1. Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice.
Ho CL; Liu IH; Wu YH; Chen LC; Chen CL; Lee WC; Chuang CH; Lee TW; Lin WJ; Shen LH; Chang CH
J Biomed Biotechnol; 2011; 2011():101497. PubMed ID: 21660132
[TBL] [Abstract][Full Text] [Related]
2. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
Liu IH; Chang CH; Ho CL; Chiu SP; Lee WC; Chang TJ; Chen LC; Wu YH; Chuang CH; Fu YK; Lee TW
Anticancer Res; 2010 Oct; 30(10):4039-48. PubMed ID: 21036718
[TBL] [Abstract][Full Text] [Related]
3. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
5. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
7. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer.
Schroeder RP; De Blois E; De Ridder CM; Van Weerden WM; Breeman WA; de Jong M
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):468-75. PubMed ID: 23069925
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.
Mansi R; Wang X; Forrer F; Kneifel S; Tamma ML; Waser B; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2009 Aug; 15(16):5240-9. PubMed ID: 19671861
[TBL] [Abstract][Full Text] [Related]
9. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the new GRPR-antagonist
Lymperis E; Kaloudi A; Kanellopoulos P; Krenning EP; de Jong M; Maina T; Nock BA
J Labelled Comp Radiopharm; 2019 Aug; 62(10):646-655. PubMed ID: 30963606
[TBL] [Abstract][Full Text] [Related]
11. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma.
Deutscher SL; Figueroa SD; Kumar SR
Nucl Med Biol; 2009 Feb; 36(2):137-46. PubMed ID: 19217525
[TBL] [Abstract][Full Text] [Related]
13. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.
Schroeder RP; Müller C; Reneman S; Melis ML; Breeman WA; de Blois E; Bangma CH; Krenning EP; van Weerden WM; de Jong M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1386-96. PubMed ID: 20182713
[TBL] [Abstract][Full Text] [Related]
14. Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA.
Bandari RP; Carmack TL; Malhotra A; Watkinson L; Fergason Cantrell EA; Lewis MR; Smith CJ
J Med Chem; 2021 Feb; 64(4):2151-2166. PubMed ID: 33534560
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging.
Zhou Z; Wagh NK; Ogbomo SM; Shi W; Jia Y; Brusnahan SK; Garrison JC
J Nucl Med; 2013 Sep; 54(9):1605-12. PubMed ID: 23896558
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites.
Linder KE; Metcalfe E; Arunachalam T; Chen J; Eaton SM; Feng W; Fan H; Raju N; Cagnolini A; Lantry LE; Nunn AD; Swenson RE
Bioconjug Chem; 2009 Jun; 20(6):1171-8. PubMed ID: 19480415
[TBL] [Abstract][Full Text] [Related]
17. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
18. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
Garrison JC; Rold TL; Sieckman GL; Naz F; Sublett SV; Figueroa SD; Volkert WA; Hoffman TJ
Bioconjug Chem; 2008 Sep; 19(9):1803-12. PubMed ID: 18712899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
